Standout Papers
- Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations (2013)
- Randomized Phase II Trial of Onartuzumab in Combination With Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer (2013)
- Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON (2022)
- Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial (2014)
Immediate Impact
2 by Nobel laureates 15 from Science/Nature 126 standout
Citing Papers
Dictionary of immune responses to cytokines at single-cell resolution
2023 StandoutNature
Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC
2023 Standout
Works of С. В. Орлов being referenced
Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non–Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial
2015
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
2013 Standout
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| С. В. Орлов | 4471 | 3934 | 2075 | 99 | 6.4k | |
| Lowell L. Hart | 2166 | 3433 | 1702 | 125 | 5.4k | |
| Alan B. Sandler | 3602 | 4405 | 2405 | 107 | 7.4k | |
| Hideki Watanabe | 3478 | 2965 | 2905 | 156 | 7.0k | |
| Rogério Lilenbaum | 5344 | 5515 | 2115 | 105 | 8.3k | |
| Ferry A.L.M. Eskens | 1446 | 2813 | 2570 | 159 | 6.2k | |
| Dirk Strumberg | 1549 | 3088 | 3495 | 139 | 7.3k | |
| Petr Zatloukal | 3368 | 3672 | 1552 | 86 | 5.6k | |
| Tae‐You Kim | 2341 | 3193 | 3081 | 150 | 7.4k | |
| Vassilis Georgoulias | 2712 | 5596 | 1856 | 179 | 7.1k | |
| Thomas E. Stinchcombe | 3619 | 3751 | 1698 | 212 | 6.7k |
All Works
Login with ORCID to disown or claim papers
Loading papers...